The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•14 April 2026•

1 min read

MindBio Deploys AI-Powered Intox Collect™ for Drug and Alcohol Detection

Key Facts

1MindBio Therapeutics completed the development of Intox Collect™ technology for collecting and analyzing voice and facial recognition data.

2The new technology uses AI to detect alcohol and substances affecting the central nervous system (CNS).

3The technology allows the company to rapidly scale data sample collection from a wide range of consumed substances.

MindBio Therapeutics has officially completed the development and deployment of its proprietary Intox Collect™ technology. This innovative system utilizes advanced AI-driven voice and facial recognition to identify intoxication from alcohol and various central nervous system (CNS) substances. The deployment marks a significant milestone in the company’s efforts to scale its data collection and analysis infrastructure rapidly. By leveraging AI, MindBio can now process data samples from a broad spectrum of consumed substances for biotechnology and diagnostic purposes. This technology is expected to enhance the company's diagnostic capabilities and market competitiveness in the AI-driven healthcare sector. Investors view this move as a positive step toward increasing the company's valuation through proprietary technological innovation.